A950130 Stock Overview
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Access Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,430.00 |
| 52 Week High | ₩14,340.00 |
| 52 Week Low | ₩6,300.00 |
| Beta | 0.20 |
| 1 Month Change | -19.22% |
| 3 Month Change | -23.45% |
| 1 Year Change | -31.08% |
| 3 Year Change | -75.78% |
| 5 Year Change | 58.57% |
| Change since IPO | -37.87% |
Recent News & Updates
Shareholder Returns
| A950130 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 0.6% | 6.5% | 0.5% |
| 1Y | -31.1% | 32.1% | 4.7% |
Return vs Industry: A950130 underperformed the KR Medical Equipment industry which returned 26.1% over the past year.
Return vs Market: A950130 underperformed the KR Market which returned 1.2% over the past year.
Price Volatility
| A950130 volatility | |
|---|---|
| A950130 Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A950130's share price has been volatile over the past 3 months.
Volatility Over Time: A950130's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 93 | Young-Ho Choi | accessbio.net |
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names.
Access Bio, Inc. Fundamentals Summary
| A950130 fundamental statistics | |
|---|---|
| Market cap | ₩217.41b |
| Earnings (TTM) | -₩3.17b |
| Revenue (TTM) | ₩348.64b |
0.6x
P/S Ratio-68.5x
P/E RatioIs A950130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950130 income statement (TTM) | |
|---|---|
| Revenue | ₩348.64b |
| Cost of Revenue | ₩178.77b |
| Gross Profit | ₩169.88b |
| Other Expenses | ₩173.05b |
| Earnings | -₩3.17b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -93.84 |
| Gross Margin | 48.73% |
| Net Profit Margin | -0.91% |
| Debt/Equity Ratio | 4.0% |
How did A950130 perform over the long term?
See historical performance and comparison